{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344666","form_type":"8-K","ticker":"MOBI","cik":"0001489993","company_name":"Mobia Medical, Inc.","filed_at":"2026-08-11T20:12:00+00:00","discovered_at":"2026-08-11T20:13:00.378999+00:00","generated_at":"2026-08-11T20:13:06.360193+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mobia Medical Q2 revenue $13.5M (+102% YoY), net loss $21.0M; FY26 guide $54-56M","bullets":["Revenue $13.5M vs $6.7M in Q2 2025, up 102%; gross margin 83.2% vs 82.3%.","Net loss $21.0M ($1.10/share) vs $10.5M loss ($12.44/share) in prior year; per-share drop reflects IPO share conversion.","Cash and equivalents $177.1M as of June 30, 2026; IPO closed May 2026 with ~$134.0M net proceeds.","FY2026 revenue guidance $54-56M, implying 69-75% growth over 2025.","Published two-year VNS-REHAB follow-up data in Neurology; appointed Myriam Curet, M.D. and Reza Zadno, Ph.D. to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344666","json":"https://secwatch.observer/filing/0001193125-26-344666.json","markdown":"https://secwatch.observer/filing/0001193125-26-344666.md","text":"https://secwatch.observer/filing/0001193125-26-344666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1489993/000119312526344666/0001193125-26-344666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1489993/000119312526344666/mobi-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:13:06.360193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}